Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating a custom GPT assistant for critical appraisal of biological variation studies by the BIVAC.

Clinical chemistry and laboratory medicine·2026
Same author

A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.

Journal of blood medicine·2026
Same author

Pre-transplant microRNA serum profiles and association with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Frontiers in immunology·2026
Same author

Biological Variation of Natriuretic Peptides and Other Cardiovascular Disease-Related Biomarkers: A Systematic Review and Meta-analysis.

Clinical chemistry·2026
Same author

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

The oncologist·2026
Same author

Endothelial mediators and association with chronic graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a retrospective single-center study.

Cytotherapy·2026

Related Experiment Video

Updated: Mar 10, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.5K

Myeloproliferative neoplasms and JAK2 mutations.

Henry Almedal1, Marta Vorland2, Aasne K Aarsand3

  • 1Det medisinsk-odontologiske fakultet Universitetet i Bergen.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|December 9, 2016
PubMed
Summary

The JAK2V617F mutation is prevalent in Norwegian myeloproliferative neoplasm patients, affecting disease characteristics. This genetic marker is crucial for diagnosing these blood disorders and understanding patient differences.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Related Experiment Videos

Last Updated: Mar 10, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Diagnostics

Background:

  • The JAK2V617F mutation, identified in 2005, revolutionized the understanding of myeloproliferative neoplasms (MPNs).
  • MPNs are a group of blood cancers characterized by the overproduction of one or more blood cell types.

Purpose of the Study:

  • To determine the prevalence of the JAK2V617F mutation in a Norwegian patient cohort undergoing MPN assessment.
  • To investigate clinical and biochemical distinctions between JAK2V617F mutation-positive and mutation-negative MPN patients.

Main Methods:

  • Retrospective analysis of JAK2V617F mutation test results from 2006-2012.
  • Correlation of mutation status with clinical data from electronic patient records.

Main Results:

  • Out of 803 patients tested, 156 (19.4%) had the JAK2V617F mutation.
  • The mutation was present in 75% of polycythaemia vera, 59.8% of essential thrombocytosis, and 50% of myelofibrosis cases.
  • Mutation-positive polycythaemia vera patients exhibited elevated platelets and leukocytes; mutation-positive essential thrombocytosis patients had high hemoglobin, hematocrit, and leukocytes. Mutation-negative patients were younger and more frequently smokers.

Conclusions:

  • The JAK2V617F mutation is a key diagnostic marker for MPNs.
  • The presence of the JAK2V617F mutation is associated with distinct clinical and biochemical phenotypes in MPN patients.